{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:22:48Z","timestamp":1791976968158,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21811"],"award-info":[{"award-number":["21811"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010686","name":"H2020 European Institute of Innovation and Technology","doi-asserted-by":"publisher","award":["777357"],"award-info":[{"award-number":["777357"]}],"id":[{"id":"10.13039\/100010686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dendritic cells are professional antigen presenting cells with the ability, in their immature state, to induce tolerance in T cells. A protocol to develop phenotypically stable tolerogenic dendritic cells (TolDC) was developed in Newcastle and cells administered to participants in the phase I AuToDeCRA study, demonstrating that TolDC were safe and well tolerated. More knowledge of the TolDC product is now needed, such as optimal dose, route of administration and antigen loading. Establishing this and developing a biomarker profile to demonstrate favourable immunomodulation is the focus of AuToDeCRA-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      AuToDeCRA-2 is a non-commercial, phase IIa, 5-arm, randomised, unblinded, single-centre study. It is designed to demonstrate and compare immunomodulation achieved by TolDC administered via three distinct routes: intra-nodal, intra-articular, intra-dermal and, in the case of intra-nodal administration, at 2 doses. Participants will be randomised to one of these four active intervention arms or standard care. Participants in intervention arms will receive a single dose of TolDC loaded with synthetic citrullinated peptides (TolDC\n                      <jats:sub>CitPep<\/jats:sub>\n                      ) representing disease relevant autoantigens. Twenty Anti-Citrullinated Peptide Antibody (ACPA) positive, shared epitope positive Rheumatoid Arthritis patients with nil-to-moderate disease activity will be randomised in an allocation ratio of 1:1:1:1:1.\n                    <\/jats:p>\n                    <jats:p>Participants will be followed up with immune state monitoring performed on peripheral blood samples at baseline, 1, 3 and 6\u00a0weeks and lymph node aspirates at baseline and 1\u00a0week, alongside clinical assessment performed throughout and additionally at 12\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>TolDC therapy is an emerging cellular therapy aimed at reversing the underlying abnormality in autoimmune disease by inducing tolerance to autoantigen. Expected challenges to this study include recruitment of potentially asymptomatic participants to a complex and intensive experimental medicine study. Limitations include the relatively small number of participants although adequate to address the aims of the study. Establishing acceptable route(s) of administration as well as demonstrating favourable immunomodulation via the development of a biomarker profile is the focus of AuToDeCRA-2, which aims to address some of the existing scientific gaps necessary for the development of TolDC therapy in autoimmune disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN, ISRCTN14999554. Registered on 27th September 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-08972-x","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:58:32Z","timestamp":1754553512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2633-3487","authenticated-orcid":false,"given":"Ema-Louise","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stanway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Goudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Phillipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Abdul Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Nice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tuckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Diboll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharien M. U.","family":"Hilkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"1","key":"8972_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","volume":"76","author":"GM Bell","year":"2017","unstructured":"Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76(1):227\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8972_CR2","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1016\/S2665-9913(20)30100-4","volume":"2","author":"JA Stanway","year":"2020","unstructured":"Stanway JA, Isaacs JD. Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. Lancet Rheumatol. 2020;2(9):e565\u201375.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"8972_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dc11-0472","volume":"34","author":"N Giannoukakis","year":"2011","unstructured":"Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34(9):2026\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"8972_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","volume":"9","author":"A Jauregui-Amezaga","year":"2015","unstructured":"Jauregui-Amezaga A, Cabez\u00f3n R, Ram\u00edrez-Morros A, Espa\u00f1a C, Rimola J, Bru C, et al. Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn\u2019s Disease: A Phase I Study. J Crohns Colitis. 2015;9(12):1071\u20138.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"8972_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S2213-8587(20)30104-2","volume":"8","author":"T Nikolic","year":"2020","unstructured":"Nikolic T, Zwaginga JJ, Uitbeijerse BS, Woittiez NJ, de Koning EJ, Aanstoot HJ, et al. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes. Lancet Diabetes Endocrinol. 2020;8(6):470\u20132.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"8972_CR6","doi-asserted-by":"publisher","first-page":"e030309","DOI":"10.1136\/bmjopen-2019-030309","volume":"9","author":"B Willekens","year":"2019","unstructured":"Willekens B, Presas-Rodr\u00edguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, et al. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open. 2019;9(9):e030309.","journal-title":"BMJ Open"},{"issue":"17","key":"8972_CR7","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1073\/pnas.1820039116","volume":"116","author":"I Zubizarreta","year":"2019","unstructured":"Zubizarreta I, Fl\u00f3rez-Grau G, Vila G, Cabez\u00f3n R, Espa\u00f1a C, Andorra M, et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci U S A. 2019;116(17):8463\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8972_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2003.tb06029.x","volume":"987","author":"RM Steinman","year":"2003","unstructured":"Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al. Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance. Ann N Y Acad Sci. 2003;987(1):15\u201325.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"8972_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1189\/jlb.1107744","volume":"84","author":"AE Anderson","year":"2008","unstructured":"Anderson AE, Sayers BL, Haniffa MA, Swan DJ, Diboll J, Wang XN, et al. Differential regulation of na\u00efve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol. 2008;84(1):124\u201333.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"8972_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1189\/jlb.0608374","volume":"85","author":"AE Anderson","year":"2009","unstructured":"Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol. 2009;85(2):243\u201350.","journal-title":"J Leukoc Biol"},{"issue":"11","key":"8972_CR11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1136\/ard.2009.126383","volume":"69","author":"RA Harry","year":"2010","unstructured":"Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis. 2010;69(11):2042\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8972_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cei.12870","volume":"187","author":"AE Anderson","year":"2017","unstructured":"Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, et al. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4(+) T cells partly via transforming growth factor-\u03b21. Clin Exp Immunol. 2017;187(1):113\u201323.","journal-title":"Clin Exp Immunol"},{"key":"8972_CR13","doi-asserted-by":"crossref","unstructured":"Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients. Science Translational Medicine. 2015;7(290):290ra87-ra87.","DOI":"10.1126\/scitranslmed.aaa9301"},{"issue":"4","key":"8972_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcn006","volume":"101","author":"AW Morgan","year":"2008","unstructured":"Morgan AW, Hale G, Rebello PR, Richards SJ, Gooi HC, Waldmann H, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM. 2008;101(4):299\u2013306.","journal-title":"QJM"},{"issue":"1","key":"8972_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1479-5876-2-27","volume":"2","author":"R Ridolfi","year":"2004","unstructured":"Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004;2(1):27.","journal-title":"J Transl Med"},{"key":"8972_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2016.00494","volume":"7","author":"C Gerstner","year":"2016","unstructured":"Gerstner C, Dubnovitsky A, Sandin C, Kozhukh G, Uchtenhagen H, James EA, et al. Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted \u03b1-Enolase T Cell Epitope in Rheumatoid Arthritis. Front Immunol. 2016;7:494.","journal-title":"Front Immunol"},{"issue":"7","key":"8972_CR17","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/art.38637","volume":"66","author":"EA James","year":"2014","unstructured":"James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 2014;66(7):1712\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"8972_CR18","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1136\/annrheumdis-2015-208495","volume":"75","author":"A Schwenzer","year":"2016","unstructured":"Schwenzer A, Jiang X, Mikuls TR, Payne JB, Sayles HR, Quirke A-M, et al. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1876\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8972_CR19","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/art.30445","volume":"63","author":"O Snir","year":"2011","unstructured":"Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA\u2013DRB1*0401\u2013positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum. 2011;63(10):2873\u201383.","journal-title":"Arthritis Rheum"},{"issue":"20","key":"8972_CR20","doi-asserted-by":"publisher","first-page":"e160964","DOI":"10.1172\/jci.insight.160964","volume":"7","author":"A Sonigra","year":"2022","unstructured":"Sonigra A, Nel HJ, Wehr P, Ramnoruth N, Patel S, van Schie KA, et al. Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis. JCI Insight. 2022;7(20):e160964.","journal-title":"JCI Insight."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08972-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:25:27Z","timestamp":1757370327000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08972-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8972"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08972-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6222488\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been granted by the NHS Health Research Authority Research Ethics Committee 23\/LO\/0494 in collaboration with MHRA CTA 17136\/0304\/001\u20130001. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A model consent form will be made available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"278"}}